Dasatinib in children and adolescents with relapsed of refractory leukemia: results of the CA 180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium

C.M. Zwaan; C Rizzari; F Mechinaud; DL Lancaster; T Lehrnbecher; Vincent van der Velden; BB Beverloo; Monique den Boer; Rob Pieters; D Reinhardt; M Dworzak; J Rosenberg; G Manos; S Agrawal; L Strauss; A Baruchel; PR Kearns

Dasatinib in children and adolescents with relapsed of refractory leukemia: results of the CA 180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium

C.M. Zwaan, C Rizzari, F Mechinaud, DL Lancaster, T Lehrnbecher, Vincent van der Velden, BB Beverloo, Monique den Boer, Rob Pieters, D Reinhardt, M Dworzak, J Rosenberg, G Manos, S Agrawal, L Strauss, A Baruchel, PR Kearns

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	2460-2468
Number of pages	9
Journal	Journal of Clinical Oncology
Volume	31
Issue number	19
Publication status	Published - 2013

Research programs

EMC MM-02-54-03
EMC MM-02-72-03

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Zwaan, C. M., Rizzari, C., Mechinaud, F., Lancaster, DL., Lehrnbecher, T., van der Velden, V., Beverloo, BB., den Boer, M., Pieters, R., Reinhardt, D., Dworzak, M., Rosenberg, J., Manos, G., Agrawal, S., Strauss, L., Baruchel, A., & Kearns, PR. (2013). Dasatinib in children and adolescents with relapsed of refractory leukemia: results of the CA 180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. Journal of Clinical Oncology, 31(19), 2460-2468.

@article{a42e3ef8da9143449eb72c4484af5d36,

title = "Dasatinib in children and adolescents with relapsed of refractory leukemia: results of the CA 180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium",

author = "C.M. Zwaan and C Rizzari and F Mechinaud and DL Lancaster and T Lehrnbecher and {van der Velden}, Vincent and BB Beverloo and {den Boer}, Monique and Rob Pieters and D Reinhardt and M Dworzak and J Rosenberg and G Manos and S Agrawal and L Strauss and A Baruchel and PR Kearns",

year = "2013",

language = "Undefined/Unknown",

volume = "31",

pages = "2460--2468",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins",

number = "19",

}

Zwaan, CM, Rizzari, C, Mechinaud, F, Lancaster, DL, Lehrnbecher, T, van der Velden, V, Beverloo, BB, den Boer, M, Pieters, R, Reinhardt, D, Dworzak, M, Rosenberg, J, Manos, G, Agrawal, S, Strauss, L, Baruchel, A & Kearns, PR 2013, 'Dasatinib in children and adolescents with relapsed of refractory leukemia: results of the CA 180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium', Journal of Clinical Oncology, vol. 31, no. 19, pp. 2460-2468.

Dasatinib in children and adolescents with relapsed of refractory leukemia: results of the CA 180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. / Zwaan, C.M.; Rizzari, C; Mechinaud, F et al.
In: Journal of Clinical Oncology, Vol. 31, No. 19, 2013, p. 2460-2468.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Dasatinib in children and adolescents with relapsed of refractory leukemia: results of the CA 180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium

AU - Zwaan, C.M.

AU - Rizzari, C

AU - Mechinaud, F

AU - Lancaster, DL

AU - Lehrnbecher, T

AU - van der Velden, Vincent

AU - Beverloo, BB

AU - den Boer, Monique

AU - Pieters, Rob

AU - Reinhardt, D

AU - Dworzak, M

AU - Rosenberg, J

AU - Manos, G

AU - Agrawal, S

AU - Strauss, L

AU - Baruchel, A

AU - Kearns, PR

PY - 2013

Y1 - 2013

M3 - Article

SN - 0732-183X

VL - 31

SP - 2460

EP - 2468

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 19

ER -